Work

Complete and Durable Response After Radiation Therapy to Primary Tumor Site of a Patient With Metastatic Anorectal Mucosal Melanoma With Oligoprogression on Nivolumab

Year: 2020

Type: article

Abstract: Mucosal melanoma is a rare subtype of melanoma, accounting for 1.4% of melanoma diagnoses in the United States.1 Median overall survival from time of diagnosis for mucosal melanoma has historically been less than that of cutaneous melanoma in part owing to the frequency of occult presentation and the relative lack of evidence-based guidelines specific to mucosal histology.2 Radiation therapy (RT) in mucosal melanoma has shown promise in certain settings but indications remain poorly defined.3,4 Immune checkpoint inhibitors have shown excellent response rates in metastatic melanoma and are increasingly used for mucosal melanoma; however, most patients will eventually progress.

Source: Advances in Radiation Oncology

DOI: 10.1016/j.adro.2020.02.006

Authors: David G. Wallington, Arif S. Rashid, Zachary S. Buchwald, Lisa J. Sudmeier, Mohammad K. Khan

Institutions: Western Michigan University, Winship Cancer Institute

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000